| Aug 7 |
ChromaDex: Q2 Earnings Snapshot
|
| Aug 7 |
ChromaDex GAAP EPS of $0.00 beats by $0.01, revenue of $22.7M misses by $0.76M
|
| Aug 7 |
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
|
| Aug 6 |
ChromaDex Q2 2024 Earnings Preview
|
| Aug 5 |
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
|
| Jul 24 |
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
|
| Jul 23 |
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
|
| Jul 22 |
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
|
| Jul 17 |
ChromaDex appoints James Lee as interim CFO
|
| Jul 16 |
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
|
